Evolving.
Delivering impact.

What does evolution really mean?

Investing
in state-of-the-art facilities and advanced development platforms for complex sterile generics and value-added medicines addressing unmet medical needs.

Creating value
through our business model, new jobs and the continuous growth of our people.

Delivering a positive impact
on health and society.

www.rafarmgroup.com

Evolving.
Delivering impact.

RAFARM is a pharmaceutical company with a strong international presence specialized in ophthalmics and complex injectables.

Building on this strong foundation, the company continues to expand its capabilities in the development of Value-Added Medicines that address unmet medical needs.

” Creating value ”

Business models



Drug development



Advanced end-to-end CDMO Solutions

B2B: Out Licensing and Supply all over the world



B2C: Marketing and promotion in local markets (Greece and Cyprus)

Evolving.
Delivering impact.

EST

1974

21,000 sq. m.
Facilities

>100
Own developments of pharmaceutical generic products

>1,350
Products with regulatory approval worldwide

12 ANDA approvals from FDA

Strong expertise in opthalmics and complex injectables

80% of our developments are ophthalmics

> 350 active ophthalmic licenses

> 160 active licenses for complex injectables

Evolving.
Delivering impact.

“Evolving”

Expanding exports worldwide

Presence in all 5 continents

Exports in 60+ countries

Doubled Exports over the past 5 years (in values)

Building trusted partnerships

Global pharmaceutical companies

Research centers

Universities

CDMO capabilities

Supporting partners across the entire product lifecycle — from development and technology transfer to manufacturing and regulatory expertise.

Annual Capacity

300,000,000
tablets

15,000,000
vials

10,000,000
ampoules

40,000,000
units of ophthalmic products

Manufacturing-own & Third Party

Manufacturing for more than 120 companies worldwide

5 production lines for ophthalmic and injectable products

NEW 2 more production lines for sterile products under development

RAFARM

Evolving.
Delivering impact.

R&D

Fixed combinations

Complex ophthalmics

- New technology platforms
- Preservative Free
- Microsuspensions
- Nanoemulsions

Injectables

- Colloids

RAFARM

Evolving.
Delivering impact.

FDA approval

12 ANDA **approvals** received from FDA

1 more ANDA approvals expected in the coming months

5 more ophthalmics under development for the US market

RAFARM

Evolving.
Delivering impact.

Quality is our fundamental principle for each process

— EU GMP approved
— US FDA approved
— Russia FMBA approved
— Australia TGA approved
— Canada HC approved
— Taiwan authorities approved
— Tunisian authorities approved
— Korea authorities approved
— Saudi Food and Drug Authority approved
— China National Medical Products Administration approved

20+
successful inspections
and audits annually

RAFARM

Evolving.
Delivering impact.

”Investing €120 mil., 2021-2027 ”

€75 mil. in R&D

9 sterile pharmaceutical products under development

5 for US

4 for EU

€45 mil. in CAPEX

New state-of-the-art R&D center (completed)

3 new production lines for steriles (completed)

New warehouse (completed)

New quality control laboratories with state-of-the-art equipment (completed)

New production facilities – 3 more lines for steriles (2 lines under development)

Evolving.
Delivering impact.

Enhancing R&D capabilities

Value Added Medicines pipeline

VAM	FORM	THERAPEUTIC AREA	STATUS			
			Preclinical Development	Clinical Development		
				Phase I	Phase II	Phase III
RFO-101	Eye Drops solution	Cataract surgery	v	v	v	v Q4 2025
RFO-201	Eye Drops emulsion	Chronic non-infectious anterior uveitis	v	v		
RFO-202	Eye Drops solution	Corneal scarring	v			

- New fixed dose combination
- Nanotechnology platform for new opthlalmic (BNS Ophthalmics) - significant unmet medical need
- Drug repurposing (Cleveland Clinic) -significant unmet medical need

Evolving.
Delivering impact.

Landmark collaboration with **Cleveland Clinic**

Development of an **innovative non-invasive ophthalmic therapy**, based on drug repurposing, to address an **unmet medical need** clearing corneas with scarring fibrosis, a condition that can compromise patient visual acuity.

RAFARM will lead the full development program, including formulation optimization, preclinical and clinical studies, large-scale manufacturing, and global commercialization.

Evolving.
Delivering impact.

BNS and RAFARM created **BNS Ophthalmics**

Leveraging nanotechnology in the development of a tacrolimus formulation for chronic non-infectious anterior uveitis

BNSO is currently engaging potential investors to participate in funding its Phase II clinical study.

BioNanoSim Ophthalmics

Evolving.
Delivering impact.

NEW state-of-the-art R&D center

R&D



Evolving.
Delivering impact.

NEW cutting-edge production line for ophthalmics

Operational January 2026

DARA



Expansion and Complete Reconstruction of Quality Control Laboratories

(physicochemical and microbiological)

RAFARM

Evolving.
Delivering impact.

NEW production facilities, 5,000 sq.m.

Sep 2026

RAFARM

Evolving.
Delivering impact.

RAFARM 2030

Building a leading international platform for complex ophthalmic, advanced sterile and value-added medicines.

Driven by expertise.
Strengthened by partnerships.



Evolving.
Delivering impact.

Contributing to a healthier future. Delivering impact.

RAFARM's ESG strategy, is founded on three key pillars:

- Green planet
- Responsible operations
- Healthy Communities

Evolving together with our people



We inspire and support our people to achieve more

We are a dynamic team that empowers talent, embraces diversity and accelerates development

Great Place To Work. Certified DEC 2024-DEC 2025 GREECE

Evolving.
Delivering impact.


#RAFARMteam
Creating Value
Evolving together
Delivering impact

Evolving.
Delivering impact.

THANK YOU